Biopharmaceutical company Clovis Oncology Inc (NASDAQ:CLVS) stated on Tuesday that it has generated Rubraca product revenues in the range of USD38.3m-USD39.3m for the fourth quarter of 2019.

This marks a rise in when compared with Rubraca product revenues of USD37.6m for the third quarter of 2019 and USD30.4m for the fourth quarter of 2018, respectively.

The company collected Rubraca product revenues in the USD142.0-USD143.0m range for the FY2019, up over USD95.4m for FY2018.

According to the company, Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in ovarian cancer as well as several additional solid tumour indications. It holds the worldwide rights for Rubraca.

Additionally, the company said it plans to discuss the results this week with investors at the 38th Annual JP Morgan Healthcare Conference in San Francisco as well as report financial results for the fourth quarter and full year ended 31 December 2019 on 24 February 2020.